Literature DB >> 3519340

Preventive effects of cyclosporin on diabetes in NOD mice.

Y Mori, M Suko, H Okudaira, I Matsuba, A Tsuruoka, A Sasaki, H Yokoyama, T Tanase, T Shida, M Nishimura.   

Abstract

Non-obese diabetic mice aged 30 to 60 days were treated orally with Cyclosporin at doses of 25, 15 and 2.5 mg/kg every 2 days until 160 days of age. Diabetes developed in 12 out of 18 oil-treated mice (67%), with partial to complete Langerhans' islet destruction associated with lymphocytic infiltration. The non-obese diabetic mice showed a plasma glucose concentration of 6.62 +/- 0.92 mmol/l (mean +/- SD) at 50 days of age. The plasma glucose level of oil-treated non-obese diabetic mice gradually increased after 130 days of age and reached 14.0 to 19.0 mmol/l at 160 days of age, while Cyclosporin-treated non-obese diabetic mice showed neither clear increase of plasma glucose levels nor development of insulitis. The cumulative incidence of diabetes in Cyclosporin-treated mice was significantly lower than that in oil-treated mice (p less than 0.01). Subsequently, Cyclosporin treatment was started after development of glucose intolerance. Twenty-five mg/kg of Cyclosporin was administered every 2 days for 35 days. Cyclosporin appeared to have little therapeutic effect on diabetes in non-obese diabetic mice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519340     DOI: 10.1007/bf00454884

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Rapid and sensitive, colorimetric determination of the anomers of D-glucose with D-glucose oxidase, peroxidase, and mutarotase.

Authors:  J Okuda; I Miwa; K Maeda; K Tokui
Journal:  Carbohydr Res       Date:  1977-10       Impact factor: 2.104

3.  Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.

Authors:  P J Tutschka; W E Beschorner; A C Allison; W H Burns; G W Santos
Journal:  Nature       Date:  1979-07-12       Impact factor: 49.962

4.  Cyclosporin-A-induced long-term survival of fully incompatible skin and heart grafts in rats.

Authors:  D J White; K Rolles; T Ottawa; O Turell
Journal:  Transplant Proc       Date:  1980-06       Impact factor: 1.066

5.  Skin grafts in rabbits with cyclosporin A: absence of induction of tolerance and untoward side effects.

Authors:  A Gratwohl; I Forster; B Speck
Journal:  Transplantation       Date:  1981-02       Impact factor: 4.939

6.  Cyclosporin prevents diabetes in BB Wistar rats.

Authors:  A Laupacis; C R Stiller; C Gardell; P Keown; J Dupre; A C Wallace; P Thibert
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

7.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study.

Authors:  A Miyazaki; T Hanafusa; K Yamada; J Miyagawa; H Fujino-Kurihara; H Nakajima; K Nonaka; S Tarui
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

9.  Prolongation of renal allograft survival in the rat by pretreatment with donor antigen and cyclosporin A.

Authors:  W P Homan; K A Williams; P R Millard; P J Morris
Journal:  Transplantation       Date:  1981-06       Impact factor: 4.939

  9 in total
  32 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice.

Authors:  K Kino; K Mizumoto; T Sone; T Yamaji; J Watanabe; A Yamashita; K Yamaoka; K Shimizu; K Ko; H Tsunoo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

Review 3.  Prediction and prevention of type I diabetes.

Authors:  R Gianani; G S Eisenbarth
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

Review 4.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

5.  Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial.

Authors:  I Conget; E Aguilera; S Pellitero; S Näf; K Bendtzen; R Casamitjana; R Gomis; F Nicoletti
Journal:  Diabetologia       Date:  2005-07-02       Impact factor: 10.122

6.  Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells.

Authors:  C Boitard; A Bendelac; M F Richard; C Carnaud; J F Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Neonatal injections of cyclosporin enhance autoimmune diabetes in non-obese diabetic mice.

Authors:  P Saï; O Senecat; L Martignat; E Gouin
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Thymus reticulum of autoimmune mice. 3. Ultrastructural study of NOD (non-obese diabetic) mouse thymus.

Authors:  B Nabarra; I Andrianarison
Journal:  Int J Exp Pathol       Date:  1991-06       Impact factor: 1.925

Review 9.  Type 1 diabetes mellitus: an imbalance between effector and regulatory T cells?

Authors:  E J Rashba; E P Reich; C A Janeway; R S Sherwin
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.